Big Cypress Acquisition Corp.

Big Cypress Acquisition Corp., trading on Nasdaq under the ticker SABS, is a blank-check company that filed its S-1 registration statement on December 7, 2020, targeting the healthcare and biopharmaceutical sector. Sponsored by Big Cypress Holdings LLC, the SPAC completed its initial public offering in late 2020. Big Cypress subsequently entered into a business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company focused on developing human polyclonal antibodies, with the transaction closing in October 2021 and the combined entity continuing to trade on Nasdaq as SABS. For full filing history, deal analytics, and real-time SPAC intelligence on Big Cypress Acquisition Corp. and thousands of other transactions, sign up for SpacDesk at spacdesk.com.